Maze Therapeutics: Interesting Science But IPO-Related And Other Risks Exist
Maze Therapeutics IPOs at $487M, targeting APOL1 Kidney Disease with MZE829 in Phase 2. Click here to read an analysis of MAZE stock now.
Breaking binary rules for GluA2-containing AMPA receptors in calcium transport
McGill University researchers have demonstrated that AMPA receptors (AMPARs), which mediate fast excitatory neurotransmission ...
eLife14d
A Titin Missense Variant Causes Atrial Fibrillation
Abstract Rare and common genetic variants contribute to the risk of atrial fibrillation (AF). Although ion channels were among the first AF candidate genes identified, rare loss-of-function variants ...
Nature21d
Missense mutations in desmin associated with familial cardiac and skeletal myopathy
We studied five patients from two families from the United States of America. In family CSM1, two out of three siblings developed proximal muscle weakness and wasting while in their twenties or ...